Avantor (NYSE:AVTR) Price Target Raised to $28.00

Avantor (NYSE:AVTRFree Report) had its price objective lifted by Barclays from $25.00 to $28.00 in a research report released on Monday, Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities analysts also recently weighed in on the company. Robert W. Baird upped their price target on Avantor from $26.00 to $27.00 and gave the stock an outperform rating in a research report on Monday. Royal Bank of Canada reaffirmed an outperform rating and set a $31.00 price target on shares of Avantor in a research report on Monday. Citigroup downgraded Avantor from a buy rating to a neutral rating and reduced their price target for the stock from $30.00 to $23.00 in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft upped their price target on Avantor from $23.00 to $25.00 and gave the stock a hold rating in a research report on Thursday, April 18th. Finally, Stifel Nicolaus upped their price target on Avantor from $27.00 to $28.00 and gave the stock a buy rating in a research report on Monday. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $27.21.

Get Our Latest Analysis on Avantor

Avantor Price Performance

Shares of AVTR opened at $26.49 on Monday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.05 and a current ratio of 1.59. The stock has a 50 day simple moving average of $22.56 and a 200 day simple moving average of $23.76. Avantor has a 52-week low of $16.63 and a 52-week high of $28.00. The firm has a market capitalization of $18.01 billion, a PE ratio of 67.92, a P/E/G ratio of 2.82 and a beta of 1.32.

Insiders Place Their Bets

In other Avantor news, insider Christophe Couturier 10,000 shares of the stock in a transaction dated Tuesday, July 30th. The was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Avantor

Several institutional investors and hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in shares of Avantor by 2,003.6% in the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after acquiring an additional 1,102 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Avantor by 125.3% in the fourth quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock worth $28,000 after acquiring an additional 694 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in shares of Avantor by 565.5% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock worth $30,000 after acquiring an additional 1,131 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Avantor by 1,830.3% in the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after acquiring an additional 1,391 shares during the last quarter. Finally, Gladius Capital Management LP bought a new position in shares of Avantor in the fourth quarter worth about $42,000. Institutional investors own 95.08% of the company’s stock.

About Avantor

(Get Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Featured Articles

Analyst Recommendations for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.